Report cover image

Global Metastatic Bone Disease Market Size Study, By End-Use (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), By Origin of Metastasis (Breast, Lung, Thyroid, Kidney, Prostate, Others), By Treatment (Medication, Radiation Therapy, Surgical Inte

Publisher Bizwit Research & Consulting
Published Jan 13, 2025
Length 285 Pages
SKU # BIZW19502978

Description

Global Metastatic Bone Disease Market Size Study, By End-Use (HospACitals, Specialty Clinics, Ambulatory Surgical Centers), By Origin of Metastasis (Breast, Lung, Thyroid, Kidney, Prostate, Others), By Treatment (Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy), and Regional Forecasts 2022-2032


This substantial growth is attributed to the rising global incidence of cancer and advancements in therapeutic approaches that include radiopharmaceuticals, bisphosphonates, and other bone-targeting agents. These innovations have significantly enhanced the effectiveness of MBD treatments, improving patient quality of life by managing pain and reducing bone resorption. The development of minimally invasive surgical techniques and the adoption of advanced imaging technologies like MRI and PET scans have further revolutionized the management of metastatic bone disease, enabling precise diagnosis and personalized care.

The increasing emphasis on palliative care and the integration of multimodal treatment strategies, such as combining medications with radiation therapy and surgical interventions, have further supported market expansion. Key regions like North America and Asia-Pacific are witnessing robust growth, driven by advanced healthcare infrastructures and the rising prevalence of cancers in emerging economies.

The competitive landscape is characterized by significant investments in R&D and the introduction of innovative treatment modalities. Leading companies are focusing on developing targeted therapies to address the diverse needs of patients while ensuring quality-of-life improvements. Regional trends also reveal promising opportunities in emerging markets, fueled by improved healthcare access and rising demand for palliative care solutions.

Major market players included in this report are:

1. Amgen, Inc.

2. Bayer AG

3. Boston Scientific Corporation

4. BTG PLC

5. Eli Lilly and Company

6. F. Hoffmann-La Roche AG

7. Fresenius Kabi

8. Medtronic

9. Merck & Co., Inc.

10. Novartis AG

11. Pfizer Inc.

12. Johnson & Johnson

13. Zimmer Biomet

14. Smith & Nephew

15. Stryker Corporation

The detailed segments and sub-segments of the market are explained below:

By End-Use:
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

By Origin of Metastasis:
• Breast
• Lung
• Thyroid
• Kidney
• Prostate
• Others

By Treatment:
• Medication
• Radiation Therapy
• Surgical Intervention
• Tumor Ablation Therapy

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:

1. The global metastatic bone disease market is projected to grow during 2024-2032.

2. Innovations in imaging technologies, such as MRI and PET scans, are driving early diagnosis and effective treatment strategies.

3. The U.S. leads the market with advanced healthcare infrastructure, while Asia-Pacific emerges as a high-growth region due to increasing cancer prevalence.

4. Multimodal treatment approaches, combining radiation therapy, medication, and surgical interventions, are gaining prominence.

5. Major players include Amgen, Bayer AG, Eli Lilly, and Boston Scientific, with a focus on developing targeted and personalized therapies.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

285 Pages
Chapter 1. Global Metastatic Bone Disease Market Executive Summary
1.1. Global Metastatic Bone Disease Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By End-Use
1.3.2. By Origin of Metastasis
1.3.3. By Treatment
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Metastatic Bone Disease Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Metastatic Bone Disease Market Dynamics
3.1. Market Drivers
3.1.1. Increasing Global Cancer Burden
3.1.2. Advancements in Imaging and Diagnostics
3.1.3. Rising Demand for Palliative Care
3.2. Market Challenges
3.2.1. High Treatment Costs
3.2.2. Limited Access to Advanced Healthcare in Developing Regions
3.3. Market Opportunities
3.3.1. Expansion of Multimodal Treatment Approaches
3.3.2. Investment in R&D for Targeted Therapies
Chapter 4. Global Metastatic Bone Disease Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Analyst Recommendations & Conclusion
Chapter 5. Global Metastatic Bone Disease Market Size & Forecasts by End-Use (2022-2032)
5.1. Hospitals
5.2. Specialty Clinics
5.3. Ambulatory Surgical Centers
Chapter 6. Global Metastatic Bone Disease Market Size & Forecasts by Origin of Metastasis (2022-2032)
6.1. Breast
6.2. Lung
6.3. Thyroid
6.4. Kidney
6.5. Prostate
6.6. Others
Chapter 7. Global Metastatic Bone Disease Market Size & Forecasts by Treatment (2022-2032)
7.1. Medication
7.2. Radiation Therapy
7.3. Surgical Intervention
7.4. Tumor Ablation Therapy
Chapter 8. Global Metastatic Bone Disease Market Size & Forecasts by Region (2022-2032)
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.2. Europe
8.2.1. UK
8.2.2. Germany
8.2.3. France
8.2.4. Spain
8.2.5. Italy
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. Australia
8.3.5. South Korea
8.3.6. Rest of Asia-Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. Saudi Arabia
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Amgen
9.1.2. Bayer
9.1.3. Boston Scientific
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Eli Lilly
9.3.2. Merck
9.3.3. Novartis
Chapter 10. Research Process
10.1. Research Attributes
10.2. Data Mining
10.3. Analysis Techniques
10.4. Data Validation
List of Tables
1. Global Metastatic Bone Disease Market Estimates & Forecasts by Region (2022-2032)
2. Global Metastatic Bone Disease Market Estimates & Forecasts by Treatment Type (2022-2032)
3. U.S. Metastatic Bone Disease Market Estimates & Forecasts (2022-2032)
4. Asia-Pacific Metastatic Bone Disease Market Estimates & Forecasts by Treatment (2022-2032)
5. Europe Metastatic Bone Disease Market Estimates & Forecasts by End-Use (2022-2032)
6. Middle East & Africa Market Segmentation by Treatment Type (2022-2032)
7. Latin America Metastatic Bone Disease Market Segmentation by Treatment (2022-2032)
8. Comparison of Top Players in the Metastatic Bone Disease Market
This list is not complete. The final report contains over 100 tables. The list may be updated in the final deliverable.
List of Figures
1. Metastatic Bone Disease Market Growth by Region (2022-2032)
2. Metastatic Bone Disease Market Segmentation by Treatment (2022-2032)
3. Key Players’ Market Share Analysis (2024)
4. North America Metastatic Bone Disease Market Growth (2022-2032)
5. Europe Market Trends by Treatment Type (2022-2032)
6. Emerging Asia-Pacific Markets for Metastatic Bone Disease
7. Technological Adoption Rates in MBD Treatments (2022-2032)
8. Competitive Landscape Overview of Major Players
This list is not complete. The final report contains over 50 figures. The list may be updated in the final deliverable.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us